Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1809 results for nice guidelines

  1. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  2. ImmunoCAP ISAC 112 for multiplex allergen testing (DG24)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  3. Maximal cytoreductive surgery for advanced ovarian cancer (IPG757)

    Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.

  4. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

    Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.

  5. NICE Communities

    Tailored content for our communities: Medicines and prescribing, general practice, social care, the public, library and knowledge services and local government.

  6. Four commonly used methods to increase physical activity (PH2)

    This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines:

  7. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  8. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  9. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  10. Monitoring and follow-up for adults with hearing loss:- What is the clinical and cost effectiveness of monitoring and follow-up for adults with hearing loss post-intervention compared with usual care?

    applicable) Why this is important:- The evidence review for the NICE guideline on hearing loss found a lack of evidence to...

  11. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

  12. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

  13. Updated menopause guidance includes discussion aid to support conversations about HRT

    Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.

  14. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)

    Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.

  15. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.